Subtopic Deep Dive
Insulin Resistance Assessment Models
Research Guide
What is Insulin Resistance Assessment Models?
Insulin Resistance Assessment Models develop and validate surrogate indices like HOMA-IR to quantify insulin resistance using fasting glucose and insulin levels, correlating them with gold-standard clamp techniques.
HOMA-IR, calculated as (fasting glucose × fasting insulin)/405, estimates insulin resistance from routine blood tests (Bonora et al., 2002, 599 citations). These models enable non-invasive assessment compared to hyperinsulinemic-euglycemic clamps. Over 10 papers in the provided list reference HOMA-IR in diabetes contexts.
Why It Matters
HOMA-IR independently predicts cardiovascular disease in type 2 diabetes patients, guiding risk stratification beyond HbA1c (Bonora et al., 2002). ESC Guidelines recommend IR assessment for cardiovascular risk management in diabetes (Rydén et al., 2013, 1934 citations; Rydén et al., 2014, 613 citations). Pioglitazone reduces stroke risk in insulin-resistant patients without diabetes (Kernan et al., 2016). Accurate IR models personalize therapies like GLP-1 agonists, which improve outcomes in IR-high patients (Davies et al., 2015; Zinman et al., 2009).
Key Research Challenges
Surrogate Accuracy vs Clamps
HOMA-IR correlates moderately with clamp-measured IR but overestimates in obese patients (Bonora et al., 2002). Validation requires direct comparisons, limited by clamp invasiveness. ESC Guidelines note surrogate limitations for precise quantification (Rydén et al., 2013).
Population Variability
IR indices vary by ethnicity, age, and metabolic syndrome presence (Ford et al., 2008). HOMA-IR predicts CVD differently across cohorts (Bonora et al., 2002). Standardization challenges hinder cross-study comparisons.
Genetic and Adipokine Factors
DPP4 as an adipokine links obesity to IR, complicating simple glucose-insulin models (Lamers et al., 2011). Genetic influences require integrated models beyond HOMA-IR. Metabolic syndrome studies highlight multifactorial IR drivers (Ford et al., 2008).
Essential Papers
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Authors Task Force Members, Lars Rydén, Peter J. Grant et al. · 2013 · European Heart Journal · 1.9K citations
The ESC Guidelines represent the views of the ESC and EASDand were arrived at after careful consideration of the available evidence at the time they were written. Health\nprofessionals are encourag...
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
Melanie J. Davies, Richard M. Bergenstal, Bruce W. Bode et al. · 2015 · JAMA · 1.1K citations
clinicaltrials.gov Identifier:NCT01272232.
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Walter N. Kernan, Catherine M. Viscoli, Karen L. Furie et al. · 2016 · New England Journal of Medicine · 1.1K citations
In this trial involving patients without diabetes who had insulin resistance along with a recent history of ischemic stroke or TIA, the risk of stroke or myocardial infarction was lower among patie...
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman, John Gerich, John B. Buse et al. · 2009 · Diabetes Care · 834 citations
OBJECTIVE To determine the efficacy and safety of liraglutide (a glucagon-like peptide-1 receptor agonist) when added to metformin and rosiglitazone in type 2 diabetes. RESEARCH DESIGN AND METHODS ...
Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial
Michael A. Nauck, Gary Meininger, Pei Chia Eng et al. · 2007 · Diabetes Obesity and Metabolism · 662 citations
Aim: To compare the efficacy and safety of sitagliptin vs. glipizide in patients with type 2 diabetes and inadequate glycaemic control [haemoglobin A 1c (HbA 1c ) ≥ 6.5 and ≤10%] on metformin monot...
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
Itamar Raz, M Hanefeld, Lei Xu et al. · 2006 · Diabetologia · 614 citations
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)
Lars Rydén, Peter J. Grant, Stefan D. Anker et al. · 2014 · Revista Española de Cardiología (English Edition) · 613 citations
Reading Guide
Foundational Papers
Start with Bonora et al. (2002) for HOMA-IR definition and CVD prediction (599 citations), then Rydén et al. (2013, 1934 citations) for clinical guidelines integrating surrogates.
Recent Advances
Kernan et al. (2016, 1073 citations) validates IR targeting post-stroke; Davies et al. (2015, 1074 citations) links IR to GLP-1 efficacy.
Core Methods
HOMA-IR formula from fasting labs (Bonora et al., 2002); correlation with clamps; DPP4 ELISA for adipokine IR (Lamers et al., 2011); metabolic syndrome clustering (Ford et al., 2008).
How PapersFlow Helps You Research Insulin Resistance Assessment Models
Discover & Search
Research Agent uses searchPapers('HOMA-IR validation clamp') to find Bonora et al. (2002), then citationGraph reveals 599 citing papers on CVD prediction, and findSimilarPapers uncovers ESC Guidelines (Rydén et al., 2013). exaSearch('insulin resistance indices diabetes') expands to 250M+ OpenAlex papers linking IR to GLP-1 therapies.
Analyze & Verify
Analysis Agent applies readPaperContent on Bonora et al. (2002) to extract HOMA-IR formula, then runPythonAnalysis computes correlations from abstract data using pandas/NumPy, verified by verifyResponse (CoVe) for accuracy. GRADE grading scores HOMA-IR evidence as high for CVD prediction, with statistical verification of hazard ratios.
Synthesize & Write
Synthesis Agent detects gaps in HOMA-IR validation for non-diabetic IR (Kernan et al., 2016), flags contradictions between DPP4 adipokine role and simple indices (Lamers et al., 2011). Writing Agent uses latexEditText for model equations, latexSyncCitations for 10-paper bibliography, latexCompile for report, and exportMermaid for IR pathway diagrams.
Use Cases
"Compute HOMA-IR from patient data and correlate with CVD risk from Bonora 2002"
Research Agent → searchPapers('HOMA-IR') → Analysis Agent → runPythonAnalysis(pandas dataframe of glucose/insulin) → matplotlib plot of risk correlations → GRADE-verified output with p-values.
"Write LaTeX review of IR models citing Rydén ESC guidelines and Bonora"
Synthesis Agent → gap detection on surrogates → Writing Agent → latexEditText('HOMA-IR section') → latexSyncCitations(10 papers) → latexCompile → PDF with equations and references.
"Find code for HOMA-IR calculators in diabetes papers"
Research Agent → paperExtractUrls(Bonora 2002) → Code Discovery → paperFindGithubRepo → githubRepoInspect → exportCsv of implementations for Python sandbox testing.
Automated Workflows
Deep Research workflow runs systematic review: searchPapers(50+ on 'insulin resistance indices') → citationGraph → structured report on HOMA-IR vs clamps. DeepScan applies 7-step analysis with CoVe checkpoints to verify Bonora (2002) predictions against ESC Guidelines. Theorizer generates hypotheses linking DPP4 (Lamers et al., 2011) to refined IR models from literature patterns.
Frequently Asked Questions
What is HOMA-IR?
HOMA-IR = (fasting glucose mg/dL × fasting insulin μU/mL) / 405 estimates beta-cell function and insulin resistance from routine labs (Bonora et al., 2002).
What methods assess insulin resistance?
Surrogates like HOMA-IR validate against euglycemic clamps; DPP4 levels link obesity to IR (Lamers et al., 2011); ESC Guidelines endorse surrogates for clinics (Rydén et al., 2013).
What are key papers?
Bonora et al. (2002, 599 citations) proves HOMA-IR predicts CVD; Rydén et al. (2013, 1934 citations) integrates into guidelines; Kernan et al. (2016) tests pioglitazone in IR.
What open problems exist?
Improving surrogate accuracy in diverse populations (Ford et al., 2008); integrating adipokines like DPP4 (Lamers et al., 2011); genetic personalization beyond HOMA-IR.
Research Diabetes Treatment and Management with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Insulin Resistance Assessment Models with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
Part of the Diabetes Treatment and Management Research Guide